Induction chemotherapies for acute leukemias typically induce morphologic 2 remission, but without allogeneic stem cell transplantation (allo-SCT), most 3 patients with high-risk genetic features subsequently relapse. [1] [2] [3] [4] [5] Allo-SCT has 4 a high morbidity and mortality, is costly, and is often precluded by age, co-5 morbidities or lack of a suitable donor. [6] [7] [8] There is an unmet need for effective 6 post-remission therapies that do not carry the toxicities and cost of allo-SCT. 9 7 8
Relapse of acute leukemia is mediated by a population of blasts that fall 9 below the threshold used to define morphologic remission, but may be 1 0 detected using sensitive flow cytometric or molecular assays. [10] [11] [12] [13] [14] In addition 1 1 to over expressing certain self-antigens, 15 leukemic blasts harbor numerous 1 2 mutations, 16 resulting in expression of tumor-specific antigens capable of 1 3 eliciting autologous CD4 + and CD8 + T cell responses. 17 This can potentially be 1 4
exploited by post-remission immunotherapy. 18, 19 1 5 1 6
The use of irradiated whole leukemia cells in vaccines for post-remission 1 7
immunotherapy is technically feasible, 20 and has the potential to elicit immune 1 8
responses against multiple leukemia-specific antigens without needing to first 1 9 define leukemia-specific T cell epitopes or patient tissue type. However, 2 0 administration of a vaccine without a suitable adjuvant is unlikely to elicit an 2 1 effective immune response and may lead to tolerance. 21, 22 The glycolipid α- acquire cellular material from irradiated tumor cells that have been treated 1 with α-GalCer, the protein content is presented as peptides via MHC 2 molecules to CD4 + and CD8 + T cells, while the α-GalCer is presented via the 3 MHC-like molecule CD1d to NKT cells. Interactions between DCs and NKT 4 cells promote CD40 signaling, leading to DC activation, which increases their 5 capacity to stimulate peptide-specific T cells. 23, 24 Significantly, vaccines 6 comprised of irradiated tumor cells pulsed with α-GalCer have been shown to 7 be effective in murine models of hematopoietic malignancies, including acute 8 myeloid leukemia (AML) and acute lymphoid leukemia (ALL), 23, 27, 28 and in 9 other malignancies. 25, 27, 29 and increased levels of regulatory T cells (Tregs). [35] [36] [37] It follows that 1 5
immunotherapy may be most effectively used during morphologic remission 1 6 after induction chemotherapy.
1 7 1 8
Here we investigated the efficacy of a vaccine comprised of irradiated 1 9 leukemia cells pulsed with α-GalCer in a murine acute leukemia model. While 2 0 vaccination was capable of eliciting a leukemia-specific T cell response in days. 43, 44 In some experiments three doses of 3 mg of cytarbine (Pfizer,
0
Auckland, New Zealand) was administered ten hours apart the day following 
1 3
(XMG1-2), all from eBioscience, Auckland, New Zealand; anti-CD11c-PE-Cy7 1 4 (N418), anti-CD4-APC (GK1.5), anti-CD8-FITC (53-6.7) anti-CD11c-APC 1 5
(N418), all from Biolegend, San Diego, USA; anti-CD8-Pacific blue (53-6.7)
1 6
anti-CD40-biotinylated (3/23), streptavidin-PE-Cy7, all from BD Bioscience.
7
Invariant NKT cells were detected using α-GalCer-loaded CD1d tetramers 1 8
(NIH Tetramer Core Facility, Atlanta, USA). To determine the effector cells responsible for vaccine-induced protection 1 9
against leukemia development, mice were vaccinated and depleted of CD4 + 2 0 or CD8 + cells two days before C1498 challenge to ensure that the depletion 2 1 would not interfere with cells potentially important for immune priming.
2
Vaccine-induced protection was reduced following depletion of either CD4 + or 2 3 CD8 + cells, suggesting that both CD4 + and CD8 + T cells mediated the 2 4 protection afforded by the vaccine ( Figure 1E ).
2 5
In the spleen, CD8α + DCs are thought to be responsible for phagocytosing 2 circulating apoptotic cells, 21 Having shown that prophylactic leukemia/α-GalCer vaccination can elicit an 1 5
anti-tumor effect, we next determined whether the vaccine could prolong 1 6 survival in mice with established leukemia. Mice inoculated with C1498 one 1 7
week before vaccination with leukemia/α-GalCer received no therapeutic 1 8 benefit, and the onset of symptoms was comparable to non-vaccinated 1 9 controls (Figure 2A ).
0 1
To explore why therapeutic vaccination of mice with established leukemia was 2 2 ineffective, we investigated the cascade of immune activation involved in α-
3
GalCer-adjuvanted vaccination. Since the adjuvant effect of α-GalCer involves 2 4
reciprocal interaction and activation of NKT cells and DCs, 47-50 we first 2 5
assessed the level of NKT cell activation by analyzing NKT cell number and 1 function in animals vaccinated seven or fourteen days after C1498 challenge. 
The interaction between DCs and NKT cells involves CD40/CD40 ligand 1 interaction that contributes to significant production of IL-12, primarily from 2 langerin + CD8α + DCs. 44 Serum IL-12 was analyzed five hours after vaccine 3 administration in the presence or absence of established leukemia, and 4 similar levels were observed ( Figure 2L ). Together, these results indicate that 5 the inefficacy of the vaccine was not attributed to a failure to activate NKT 6 cells or DCs. induction of leukemia-specific CD4 + T cells was impaired.
2 5 
cells were isolated 20 days after leukemia challenge and cultured with CFSE-1 labeled lymphocytes, the proliferation of CD4 + T cells was significantly 2 reduced relative to cultures containing CD11b + cells from control mice, 3 suggesting greater suppressive activity on a per cell basis ( Figure 4F ).
4
Although a trend towards reduced CD8 + T cell proliferation was also observed, was reduced in the spleens of mice with untreated leukemia, mice treated with 2 5 CD8 + T cells (CD44 hi ) to Tregs was increased in both the spleen and liver of 1 8
vaccinated mice relative to untreated animals and was also unaffected by 1 9 cytarabine pretreatment. We observed a similar trend in the ratio of effector 2 0
CD4 + T cells (CD44 hi ) to Tregs, again establishing that the addition of 2 1 cytarabine did not impact the vaccine-induced response in leukemic mice
The different treatments were associated with significant changes in responses and suggests rather, that the therapies may be successfully 1 5
combined. Importantly, chemotherapy to induce minimal residual disease for 1 6 acute leukemia may provide a window for immunotherapy.
1 7 1 8 1 9
Vaccination following cytarabine treatment protects against leukemia 2 0 rechallenge 2 1
Since cytarbine pretreatment did not negatively impact vaccine-induced 2 2 immune responses, we next assessed the efficacy of the leukemia/α-GalCer 2 3
vaccine as a post-remission therapy ( Figure 7A ). Mice were challenged with 2 4
C1498 and then treated with cytarabine. After 20 days, one group was 2 5 
displaying immunologic activity, the vaccine did not delay disease progression 1 in mice with established disease, at least in part due to leukemia-related 2 immunosuppressive activities. However, in animals that were in remission 3 following cytarabine chemotherapy, the vaccine protected against leukemia 4 rechallenge.
6
The glycolipid α -GalCer acts as an adjuvant via a third-party mechanism by 7 binding to CD1d on DCs and recruiting NKT cells to create a stimulatory mice, IFN-γ production by CD4 + , but not CD8 + T cells was impaired.
5
Interestingly, MDSCs from leukemic mice induced a more pronounced 1 6 suppression of CD4 + T cells compared to those harvested from non-leukemic 1 7
animals, although we were unable to show a similar reproducible effect on 1 8
CD8 + T cells. Also, the potent suppression of T cell proliferation by the 1 9
leukemia cells themselves appeared to be greater on CD4 + T cells than on 2 0 CD8 + T cells. It is possible therefore that the leukemic environment induces 2 1 broad CD4 + T cell dysfunction, perhaps including the inability to provide T cell 2 2 help to CD8 + T cells. In this context, it is notable that vaccine efficacy in the 2 3
prophylactic setting was dependent on langerin + CD8α + DCs, which have 2 4 been shown to have a potent capacity for stimulating cytotoxic T cells; the 2 5
vaccine may ultimately depend on CD4 + T cell help to mobilize effective 1 cytotoxic T cells through these DCs. However, given that some anti-tumor 2 activity was seen in the absence of CD8 + T cells, other CD4 + T cell functions 3 must be involved, perhaps as effectors in their own right, 67 or through 4 interactions with other MHC class II-expressing cells.
6
Other groups have also shown that α-GalCer pulsed acute leukemia cells can leukemia can also be invoked during remission after cytarabine chemotherapy.
5
As this chemotherapeutic agent is in routine clinical use for leukemia induction 1 6
and consolidation, 68,69 these results are of particular relevance clinically. 27,29 1 7
Our results support a previous in vivo study with C1498, in which mice treated We have demonstrated successful combination of immunotherapy following 2 4 chemotherapy pretreatment of leukemic mice, and have shown that
cytarabine alone did not induce changes to the immune environment that 1 could be detected by day 20. Given the suppressive effects of C1498, we 2 expected that cytarabine pretreatment would have alleviated some of the 3 leukemia-induced suppression and consequently, more robust immune 4 responses would be detected in mice that received the combined treatment.
In contrast to this, we observed little improvement in vaccine-mediated 6 responses following cytarabine. We expect that although the leukemic burden 
6
It may be possible that earlier administration of the vaccine following 1 7 cytarabine treatment could generate more robust immune responses in this 1 8
group. Since we also found little evidence to support a role for cytarabine in 1 9
modulating proportions of Tregs and MDSCs, the efficacy against rechallenge 2 0
we observe when cytarabine is combined with vaccination may simply reflect 2 1 the capacity of this drug to drastically reduce the burden of leukemia cells, 2 2 and the pre-existing immunity afforded by the vaccine before rechallenge.
2 3 2 4
In comparison to vaccination with defined antigens, an α-GalCer-loaded 1 autologous whole cell vaccine for acute leukemia has the advantages of 2 stimulating both innate and adaptive immunity, and covering a broad range of 
0
Mice were challenged with C1498 cells and 24 hours three 3 mg doses of cytarabine 2 1
percentage of PD-1 + CD8 + and CD4 + T cells in the bone marrow (J, K), respectively. For personal use only. on May 3, 2017. by guest www.bloodjournal.org From
